Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Avanir Pharmaceuticals (AMEX:AVN)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials
Recent Events
Aug  9Earnings Announcement
Location
11388 Sorrento Valley Road, Suite 200
San Diego, CA 92121
Phone: (858) 622-5200
Fax: (858) 658-7447
Employees (last reported count): 30
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 4%
·Over the last 6 months:
 · one insider buy; 1,000  shares
·Institutional: 6% (6% of float)
(36 institutions)
·Net Inst. Buying: 1.47M shares (+30.80%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Avanir Pharmaceuticals is an emerging specialty pharmaceuticals and antibody generation services company engaged in the discovery, development and licensing of therapeutic products to treat chronic human diseases. In July 2000, the United States Food and Drug Administration approved the new drug application for the Company's lead therapeutic product, docosanol 10% cream, a topical treatment for recurrent oral-facial herpes infections, commonly known as cold sores and fever blisters. SmithKline Beecham began manufacturing and distributing docosanol 10% cream for the Company in the United States under the trade name Abreva in October 2000 under an exclusive license agreement for the North American market.
More from Market Guide: Expanded Business Description

Financial Summary
Avanir Pharmaceuticals is a developmental stage company organized to discover, develop, and market novel therapeutic products to treat human diseases. For the nine months ended 6/30/01, total revenues rose from $1.2 million to $7.8 million. Net loss applicable to Common fell 80% to $1.6 million Revenues reflect higher sales of Abreva and an increase in government grant and interest income. Net income reflects the absence of $4.1 million in litigation settlement fees.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

Gerald Yakatan, Ph.D., 58
Pres, CEO
$316K
Gregory Hanson, 54
CFO, VP-Fin., Sec.
145K
J. David Hansen, 49
VP- Commercial Devel.
179K
James Berg, 49
VP of Clinical and Regulatory Affairs
135K
Dollar amounts are as of 30-Sep-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- AMEX:AVNAs of 31-Aug-2001
Price and Volume
52-Week Low
on 27-Dec-2000
$2.75 
Recent Price$4.01 
52-Week High
on 2-Oct-2000
$9.50 
Beta1.90 
Daily Volume (3-month avg)160.1K
Daily Volume (10-day avg)92.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-37.1%
52-Week Change
relative to S&P500
-15.6%
Share-Related Items
Market Capitalization$231.3M
Shares Outstanding57.7M
Float55.3M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$0.36 
Earnings (ttm)$0.10 
Earnings (mrq)-$0.04 
Sales (ttm)$0.29 
Cash (mrq)$0.33 
Valuation Ratios
Price/Book (mrq)11.11 
Price/Earnings (ttm)41.77 
Price/Sales (ttm)13.71 
Income Statements
Sales (ttm)$17.3M
EBITDA (ttm)$6.82M
Income available to common (ttm)$5.71M
Profitability
Profit Margin (ttm)33.6%
Operating Margin (ttm)33.6%
Fiscal Year
Fiscal Year EndsSep 30
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)25.94%
Return on Equity (ttm)28.29%
Financial Strength
Current Ratio (mrq)10.40 
Debt/Equity (mrq)0.00 
Total Cash (mrq)$18.7M
Short Interest
As of 8-Aug-2001
Shares Short996.0K
Percent of Float1.8%
Shares Short
(Prior Month)
0 
Short Ratio10.95 
Daily Volume91.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.